OM-85 is an immunomodulator of interferon-β production and inflammasome activity

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Dang, A T ^a   Pasquali, C ^b   Ludigs, K ^a,c   Guarda, G ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Vifor (International) Inc   (Switzerland)

^c Roche Pharma Schweiz AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BRONCHO-VAXOM; CELL EXTRACT; IMMUNOLOGICAL ADJUVANT; INFLAMMASOME; INTERLEUKIN 1; MYD88 PROTEIN, MOUSE; MYELOID DIFFERENTIATION FACTOR 88; TICAM-1 PROTEIN, MOUSE; VESICULAR TRANSPORT ADAPTOR PROTEIN;

ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; DENDRITIC CELL; DRUG EFFECT; GENETICS; KNOCKOUT MOUSE; METABOLISM; PERITONITIS;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADJUVANTS, IMMUNOLOGIC; ANIMALS; BONE MARROW CELLS; CELL EXTRACTS; CELLS, CULTURED; DENDRITIC CELLS; INFLAMMASOMES; INTERFERON-BETA; INTERLEUKIN-1; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; PERITONITIS;

EID: 85014738526     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep43844     Document Type: Article

References (68)

1. Barnes, P. J. The cytokine network in asthma and chronic obstructive pulmonary disease. The Journal of clinical investigation 118, 3546-3556 (2008).
2. Wark, P. A. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. The Journal of experimental medicine 201, 937-947 (2005).
3. Contoli, M. et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nature medicine 12, 1023-1026 (2006).
4. Platanias, L. C. Mechanisms of type-I-and type-II-interferon-mediated signalling. Nature reviews. Immunology 5, 375-386 (2005).
5. Ludigs, K., Parfenov, V., Du Pasquier, R. A. & Guarda, G. Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cell Mol Life Sci 69, 3395-3418 (2012).
6. Simon, H. U., Seelbach, H., Ehmann, R. & Schmitz, M. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy 58, 1250-1255 (2003).
7. Kumagai, Y. et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 27, 240-252 (2007).
8. Shahangian, A. et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. The Journal of clinical investigation 119, 1910-1920 (2009).
9. Goritzka, M. et al. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. The Journal of experimental medicine 212, 699-714 (2015).
10. Meissner, N., Swain, S., McInnerney, K., Han, S. & Harmsen, A. G. Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice. The American journal of pathology 176, 2806-2818 (2010).
11. Arimori, Y. et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral research 99, 230-237 (2013).
12. Zdrenghea, M. T., Makrinioti, H., Muresan, A., Johnston, S. L. & Stanciu, L. A. The role of macrophage IL-10/innate IFN interplay during virus-induced asthma. Reviews in medical virology 25, 33-49 (2015).
13. Martinez, F. D. The connection between early life wheezing and subsequent asthma: The viral march. Allergologia et immunopathologia 37, 249-251 (2009).
14. Sly, P. D., Kusel, M. & Holt, P. G. Do early-life viral infections cause asthma The Journal of allergy and clinical immunology 125, 1202-1205 (2010).
15. Murray, C. S., Simpson, A. & Custovic, A. Allergens, viruses, and asthma exacerbations. Proceedings of the American Thoracic Society 1, 99-104 (2004).
16. De Nardo, D., De Nardo, C. M. & Latz, E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. The American journal of pathology 184, 42-54 (2014).
17. Ather, J. L., Martin, R. A., Ckless, K. & Poynter, M. E. Inflammasome Activity in Non-Microbial Lung Inflammation. Journal of environmental immunology and toxicology 1, 108-117 (2014).
18. Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821-832 (2010).
19. Gross, O., Thomas, C. J., Guarda, G. & Tschopp, J. The inflammasome: an integrated view. Immunological reviews 243, 136-151 (2011).
20. Rathinam, V. A. & Fitzgerald, K. A. Inflammasome Complexes: Emerging Mechanisms and Effector Functions. Cell 165, 792-800 (2016).
21. Guarda, G. et al. Differential Expression of NLRP3 among Hematopoietic Cells. Journal of immunology 186, 2529-2534 (2011).
22. Xiao, T. S. The nucleic acid-sensing inflammasomes. Immunological reviews 265, 103-111 (2015).
23. Lupfer, C., Malik, A. & Kanneganti, T. D. Inflammasome control of viral infection. Current opinion in virology 12, 38-46 (2015).
24. Allen, I. C. et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 30, 556-565 (2009).
25. Thomas, P. G. et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 30, 566-575 (2009).
26. Ichinohe, T., Lee, H. K., Ogura, Y., Flavell, R. & Iwasaki, A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. The Journal of experimental medicine 206, 79-87 (2009).
27. McAuley, J. L. et al. Activation of the NLRP3 inflammasome by IAV virulence protein PB1-F2 contributes to severe pathophysiology and disease. PLoS pathogens 9, e1003392 (2013).
28. Gasse, P. et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. The Journal of clinical investigation 117, 3786-3799 (2007).
29. Gasse, P. et al. Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. American journal of respiratory and critical care medicine 179, 903-913 (2009).
30. Kuipers, M. T. et al. Ventilator-induced lung injury is mediated by the NLRP3 inflammasome. Anesthesiology 116, 1104-1115 (2012).
31. Dostert, C. et al. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320, 674-677 (2008).
32. Hornung, V. et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature immunology 9, 847-856 (2008).
33. Dostert, C., Ludigs, K. & Guarda, G. Innate and adaptive effects of inflammasomes on T cell responses. Current opinion in immunology 25, 359-365 (2013).
34. Okada, S. et al. Potential role of interleukin-1 in allergen-induced late asthmatic reactions in guinea pigs: suppressive effect of interleukin-1 receptor antagonist on late asthmatic reaction. J Allergy Clin Immunol 95, 1236-1245 (1995).
35. Schmitz, N., Kurrer, M. & Kopf, M. The IL-1 receptor 1 is critical for Th2 cell type airway immune responses in a mild but not in a more severe asthma model. Eur J Immunol 33, 991-1000 (2003).
36. Nakae, S. et al. IL-1 is required for allergen-specific Th2 cell activation and the development of airway hypersensitivity response. Int Immunol 15, 483-490 (2003).
37. Li, T. et al. Pharmacokinetics and anti-asthmatic potential of non-parenterally administered recombinant human interleukin-1 receptor antagonist in animal models. J Pharmacol Sci 102, 321-330 (2006).
38. Kool, M., Fierens, K. & Lambrecht, B. N. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 61, 927-934 (2012).
39. Allen, I. C. et al. Analysis of NLRP3 in the development of allergic airway disease in mice. Journal of immunology 188, 2884-2893 (2012).
40. Holt, P. G. et al. Drug development strategies for asthma: in search of a new paradigm. Nature immunology 5, 695-698 (2004).
41. Spellberg, B., Bartlett, J. G. & Gilbert, D. N. The future of antibiotics and resistance. The New England journal of medicine 368, 299-302 (2013).
42. Karchmer, A. W. Increased antibiotic resistance in respiratory tract pathogens: PROTEKT US-an update. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 39 Suppl 3, S142-150 (2004).
43. Paupe, J. Immunotherapy with an oral bacterial extract (OM-85 BV) for upper respiratory infections. Respiration; international review of thoracic diseases 58, 150-154 (1991).
44. Collet, J. P. et al. Stimulation of nonspecific immunity to reduce the risk of recurrent infections in children attending day-care centers. The Epicreche Research Group. The Pediatric infectious disease journal 12, 648-652 (1993).
45. Schaad, U. B., Mutterlein, R., Goffin, H. & Group, B. V.-C. S. Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest 122, 2042-2049 (2002).
46. Razi, C. H. et al. The immunostimulant OM-85 BV prevents wheezing attacks in preschool children. The Journal of allergy and clinical immunology 126, 763-769 (2010).
47. Schaad, U. B. OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World journal of pediatrics: WJP 6, 5-12 (2010).
48. Navarro, S. et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal immunology 4, 53-65 (2011).
49. Fu, R. et al. Broncho-Vaxom attenuates allergic airway inflammation by restoring GSK3beta-related T regulatory cell insufficiency. PloS one 9, e92912 (2014).
50. Han, L. et al. A bacterial extract of OM-85 Broncho-Vaxom prevents allergic rhinitis in mice. American journal of rhinology & allergy 28, 110-116 (2014).
51. Luan, H. et al. OM85-BV induced the productions of IL-1beta, IL-6, and TNF-alpha via TLR4-and TLR2-mediated ERK1/2/NFkappaB pathway in RAW264.7 cells. Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research 34, 526-536 (2014).
52. Roth, M. & Block, L. H. Distinct effects of Broncho-Vaxom (OM-85 BV) on gp130 binding cytokines. Thorax 55, 678-684 (2000).
53. Huber, M., Mossmann, H. & Bessler, W. G. Th1-orientated immunological properties of the bacterial extract OM-85-BV. European journal of medical research 10, 209-217 (2005).
54. Scott, N. M. et al. Protection against maternal infection-associated fetal growth restriction: proof-of-concept with a microbialderived immunomodulator. Mucosal immunology (2016).
55. Bessler, W. G., Vor dem Esche, U. & Masihi, N. The bacterial extract OM-85 BV protects mice against influenza and Salmonella infection. International immunopharmacology 10, 1086-1090 (2010).
56. Pasquali, C. et al. Enhanced Mucosal Antibody Production and Protection against Respiratory Infections Following an Orally Administered Bacterial Extract. Frontiers in medicine 1, 41 (2014).
57. Edwards, S. et al. TLR7 stimulation of APCs results in inhibition of IL-5 through type I IFN and Notch signaling pathways in human peripheral blood mononuclear cells. Journal of immunology 190, 2585-2592 (2013).
58. Biondo, C. et al. Recognition of yeast nucleic acids triggers a host-protective type I interferon response. European journal of immunology 41, 1969-1979 (2011).
59. Hemmi, H., Kaisho, T., Takeda, K. & Akira, S. The roles of Toll-like receptor 9, MyD88, and DNA-dependent protein kinase catalytic subunit in the effects of two distinct CpG DNAs on dendritic cell subsets. Journal of immunology 170, 3059-3064 (2003).
60. Waibler, Z. et al. Excessive CpG 1668 stimulation triggers IL-10 production by cDC that inhibits IFN-alpha responses by pDC. European journal of immunology 38, 3127-3137 (2008).
61. Parola, C. et al. Selective activation of human dendritic cells by OM-85 through a NF-kB and MAPK dependent pathway. PloS one 8, e82867 (2013).
62. Kim, E. Y. et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nature medicine 14, 633-640 (2008).
63. Ahanchian, H., Jones, C. M., Chen, Y. S. & Sly, P. D. Respiratory viral infections in children with asthma: do they matter and can we prevent them BMC pediatrics 12, 147 (2012).
64. Van de Craen, M., Declercq, W., Van den brande, I., Fiers, W. & Vandenabeele, P. The proteolytic procaspase activation network: an in vitro analysis. Cell death and differentiation 6, 1117-1124 (1999).
65. Guarda, G. et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 34, 213-223 (2011).
66. Yamamoto, M. et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301, 640-643 (2003).
67. Adachi, O. et al. Targeted disruption of the MyD88 gene results in loss of IL-1-and IL-18-mediated function. Immunity 9, 143-150 (1998).
68. Guarda, G. et al. T cells dampen innate immune responses through inhibition of NLRP1 and NLRP3 inflammasomes. Nature 460, 269-273 (2009).